TCR2 Therapeutics Inc. Common Stock
TCRR
TCRR was delisted on the 31st of May, 2023.
45 hedge funds and large institutions have $203M invested in TCR2 Therapeutics Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 27 increasing their positions, 4 reducing their positions, and 3 closing their positions.
575% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 4
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
33% more capital invested
Capital invested by funds: $152M → $203M (+$50.7M)
16.73% more ownership
Funds ownership: 42.25% → 58.99% (+17%)
13% more funds holding
Funds holding: 40 → 45 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$3.7M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$2.22M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$1.14M |
| 4 |
BlackRock
New York
|
+$931K |
| 5 |
Millennium Management
New York
|
+$776K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$1.11M |
| 2 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$902K |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$21.6K |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
-$7.99K |
| 5 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
-$3K |
TCRR Hedge Fund Activity: Q4 2019 in Review
45 of the 5,093 institutional investors tracked by Wall St. Rank reported a position in TCR2 Therapeutics Inc. Common Stock (TCRR) for Q4 2019, worth a combined $203M — up 33% from $152M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new TCRR positions and 3 closed out — a net gain of 5 holders — while 27 added to existing stakes and 4 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $3.7M. The largest seller was Artal Group, cutting an estimated $1.11M.
- 45 institutional investors held TCR2 Therapeutics Inc. Common Stock (TCRR) as of Q4 2019, up from 40 in Q3 2019.
- Funds reported $203M of TCR2 Therapeutics Inc. Common Stock stock for Q4 2019, up 33% quarter-over-quarter.
- 8 funds opened new TCR2 Therapeutics Inc. Common Stock positions in Q4 2019 and 3 closed out, a net change of +5 holders.
- The largest TCR2 Therapeutics Inc. Common Stock buyer in Q4 2019 was EcoR1 Capital, an estimated $3.7M added.
- The largest TCR2 Therapeutics Inc. Common Stock seller in Q4 2019 was Artal Group, an estimated $1.11M sold.
Based on aggregated 13F filings for Q4 2019.